Auris Medical, a biotech developing treatments for tinnitus and other inner ear disorders, raised $56 million by offering 9.4 million shares at $6, consistent with the revised terms filed with the SEC on Tuesday. Auris Medical plans to list on the NASDAQ under the symbol EARS. Auris Medical initially filed confidentially on 3/18/2014. Jefferies & Co. and Leerink Partners acted as lead managers on the deal.
